Multiple phosphaturic mesenchymal tumors associated with oncogenic osteomalacia: Case report and review of the literature

Ear, Nose and Throat Journal

Volumn 89, Issue 6, 2010, Pages

  Peterson, Nathan R ^a   Summerlin, Don John ^a   Cordes, Susan R ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; COCAINE; PARATHYROID HORMONE; POTASSIUM DIHYDROGEN PHOSPHATE; VITAMIN D;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BENIGN TUMOR; BLOOD CHEMISTRY; CALCIUM BLOOD LEVEL; CANCER SURGERY; CASE REPORT; DYSPNEA; EMERGENCY WARD; FEMALE; FIBROMYALGIA; FOLLOW UP; HEMANGIOPERICYTOMA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HYPOPHOSPHATEMIA; INTUBATION; KYPHOSIS; LUNG FIBROSIS; MAXILLARY SINUS; MUSCLE STRENGTH; MUSCULOSKELETAL PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL BONE; ONCOGENIC OSTEOMALACIA; OSTEOCLAST; OSTEOID OSTEOMA; OSTEOPENIA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHYSICAL EXAMINATION; PIGEON THORAX; RANGE OF MOTION; SCOLIOSIS; SMOKING; TIBIA; TRACHEOTOMY; TUMOR BIOPSY; TUMOR VASCULARIZATION; WHOLE BODY IMAGING;

EID: 77953780502     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med 1947; 16 (61): 33-46.
2. Prader A, Illig R, Uehlinger E, Stalder G. Rickets following bone tumor [in German]. Helv Paediatr Acta 1959; 14:554-65.
3. Nakahama H, Nakanishi T, Uno H, et al. Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int 1995; 55 (1): 38-40.
4. Reese DM, Rosen PJ. Oncogenic osteomalacia associated with prostate cancer. J Urol 1997; 158 (3 Pt 1): 887. (Pubitemid 27340341)
5. Ben-Baruch D, Ziv Y, Sandbank J, Wolloch Y. Oncogenic osteomalacia induced by schwannoma in a patient with neurofibromatosis. Eur J Surg Oncol 1994; 20 (1): 57-61. (Pubitemid 24104951)
6. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia- associated mesenchymal tumors are a single histopathologic entity: An analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004; 28 (1): 1-30.
7. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 1987; 59 (8): 1442-54.
8. Gonzalez-Compta X, Mañós-Pujol M, Foglia-Fernandez M, et al. Oncogenic osteomalacia: Case report and review of head and neck associated tumours. J Laryngol Otol 1998; 112 (4): 389-92. (Pubitemid 28233970)
9. Renton P, Shaw DG. Hypophosphatemic osteomalacia secondary to vascular tumors of bone and soft tissue. Skeletal Radiol 1976; 1 (1): 21-4.
10. Weiss D, Bar RS, Weidner N, et al. Oncogenic osteomalacia: Strange tumours in strange places. Postgrad Med J 1985; 61 (714): 349-55. (Pubitemid 15113184)
11. Weidner N, Bar RS, Weiss D, Strottmann MP. Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer 1985; 55 (8): 1691-1705.
12. Avila NA, Skarulis M, Rubino DM, Doppmann JL. Oncogenic osteomalacia: Lesion detection by MR skeletal survey. AJR Am J Roentgenol 1996; 167 (2): 343-5. (Pubitemid 26266164)
13. Fukumoto S, Takeuchi Y, Nagano A, Fujita T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 1999; 25 (3): 375-7. (Pubitemid 29406065)
14. Lee HK, Sung WW, Solodnik P, Shimshi M. Bone scan in tumor-induced osteomalacia. J Nucl Med 1995; 36 (2): 247-9.
15. Carpenter TO, Ellis BK, Insogna KL, et al. Fibroblast growth factor 7: An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 2005; 90 (2): 1012-20.
16. Clunie GP, Fox PE, Stamp TC. Four cases of acquired hypophosphataemic ('oncogenic') osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology (Oxford) 2000; 39 (12): 1415-21.
17. Ungari C, Rocchi G, Rinna C, et al. Hypophosphaturic mesenchymal tumor of the ethmoid associated with oncogenic osteomalacia. J Craniofac Surg 2004; 15 (3): 523-7.
18. Yang IM, Park YK, Hyun YJ, et al. Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the oral cavity: A case report. Korean J Intern Med 1997; 12 (1): 89-95.
19. Mori Y, Ogasawara T, Motoi T, et al. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109 (3): e57-63.
20. Shelekhova KV, Kazakov DV, Michal M. Sinonasal phosphaturic mesenchymal tumor (mixed connective tissue variant): Report of 2 cases [letter& rsqb;. Am J Surg Pathol 2010; 34 (4): 596-7.
21. Viscasillas G, Maiz J, Lao X, et al. Oncogenic osteomalacia due to phosphaturic mesenchymal tumor in infratemporal fossa [in Spanish]. Acta Otorrinolaringol Esp 2010 Feb. 19 [Epub ahead of print].
22. Woo VL, Landesberg R, Imel EA, et al. Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108 (6): 925-32.
23. Savage CR, Zimmer LA. Oncogenic osteomalacia from pterygopalatine fossa mass. J Laryngol Otol 2009; 123 (9): 1052-4.
24. Yun KI, Kim DH, Pyo SW. A phosphaturic mesenchymal tumor of the floor of the mouth with oncogenic osteomalacia: Report of a case. J Oral Maxillofac Surg 2009; 67 (2): 402-5.
25. Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx 2009; 36 (1): 104-5.
26. Kaylie DM, Jackson CG, Gardner EK. Oncogenic osteomalacia caused by phosphaturic mesenchymal tumor of the temporal bone. Otolaryngol Head Neck Surg 2006; 135 (4): 653-4.
27. Koriyama N, Nishimoto K, Kodama T, et al. Oncogenic osteomalacia in a case with a maxillary sinus mesenchymal tumor. Am J Med Sci 2006; 332 (3): 142-7. (Pubitemid 44401237)
28. Reis-Filho JS, Paiva ME, Lopes JM. August 2003: 47-year-old female with a 7-year history of osteomalacia and hypophosphatemia. Brain Pathol 2004; 14 (1): 111-12, 115.
29. Wilkins GE, Granleese S, Hegele RG, et al. Oncogenic osteomalacia: Evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab 1995; 80 (5): 1628-34.
30. Sweet RA, Males JL, Hamstra AJ, DeLuca HF. Vitamin D metabolite levels in oncogenic osteomalacia. Ann Intern Med 1980; 93 (2): 279-80.
31. Jefferis AF, Taylor PC, Walsh-Waring GP. Tumor-associated hypophosphataemic osteomalacia occurring in a patient with an odontogenic tumour of the maxilla. J Laryngol Otol 1985; 99 (10): 1011-17.
32. Cai Q, Hodgson SF, Kao PC, et al. Brief report: Inhibition of renal phosphate transport by a tumor product in a patient with osteomalacia. N Engl J Med 1994; 330 (23): 1645-9.
33. Rowe PS, Ong AC, Cockerill FJ, et al. Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia. Bone 1996; 18 (2): 159-69.
34. Larsson T, Zahradnik R, Lavigne J, et al. Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. Eur J Endocinol 2003; 148 (2): 269-76. (Pubitemid 36305695)
35. Bowe AE, Finnegan R, Jan de Beur SM, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001; 284 (4): 977-81.
36. Ogose A, Hotta T, Emura I, et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol 2001; 30 (2): 99-103.